The inclusion of premenopausal control samples has the potential to skew the results to higher binding of CA125 to the immune cells, and therefore one might argue that it reduces the differential between the control and the ovarian cancer cohorts. The gene discussed is MUC16; the disease is ovarian carcinoma.